The second revolution in gene therapy that has cured Javier, a child with a lethal error in the X chromosome
By Oriol Güell,
El País
| 02. 17. 2025
A “small strand of blood in the poop.” This was the first sign, initially viewed as unimportant, that put Jesús Lunar and Cristina López on the trail that something was happening with their son’s health. Javier had been born on June 12, 2020, and before the discovery, which occurred a few days later, everything had been following the chaotic routines that new members of any family impose. Six months later, however, the doctors sat the couple down and gave them the news that was going to change their lives.
“We were told that Javier had Wiskott-Aldrich syndrome, a rare genetic disease that affects the immune system. At first we didn’t know how to react, it was hard for us to accept that it could be fatal. But then something in your head clicks. You tell yourself that you have to keep going and that everything that needs to be done will be done. And so it has been to this day,” says this computer programmer born in 1982.
Javier is almost five years old now and, apart from some minor...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...